Integragen (ALINT) - Total Liabilities

Latest as of June 2025: €3.26 Million EUR ≈ $3.82 Million USD

Based on the latest financial reports, Integragen (ALINT) has total liabilities worth €3.26 Million EUR (≈ $3.82 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Integragen - Total Liabilities Trend (2008–2024)

This chart illustrates how Integragen's total liabilities have evolved over time, based on quarterly financial data. Explore Integragen long-term investment allocation to see how much of total assets are deployed in long-term investments.

Integragen Competitors by Total Liabilities

The table below lists competitors of Integragen ranked by their total liabilities.

Company	Country	Total Liabilities
TrustBIX Inc V:TBIX	Canada	CA$3.35 Million
The Alumasc Group plc LSE:ALU	UK	GBX45.48 Million
Enlivex Therapeutics Ltd TA:ENLV	Israel	ILA3.46 Million
Avation PLC LSE:AVAP	UK	GBX762.44 Million
Sarawak Cable Bhd KLSE:5170	Malaysia	RM466.66 Million
River and Mercantile UK Micro Cap Investment Company Ltd LSE:RMMC	UK	GBX213.28K
Insplorion AB ST:INSP	Sweden	Skr3.60 Million

Liability Composition Analysis (2008–2024)

This chart breaks down Integragen's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Integragen assets under control.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.19	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	9.66	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.91	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Integragen's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Integragen (2008–2024)

The table below shows the annual total liabilities of Integragen from 2008 to 2024.

Year	Total Liabilities	Change
2024-12-31	€3.76 Million ≈ $4.39 Million	-37.24%
2023-12-31	€5.99 Million ≈ $7.00 Million	-12.21%
2022-12-31	€6.82 Million ≈ $7.98 Million	-8.03%
2021-12-31	€7.42 Million ≈ $8.67 Million	+11.55%
2020-12-31	€6.65 Million ≈ $7.77 Million	+56.88%
2019-12-31	€4.24 Million ≈ $4.96 Million	-26.77%
2018-12-31	€5.79 Million ≈ $6.77 Million	+22.68%
2017-12-31	€4.72 Million ≈ $5.52 Million	-25.18%
2016-12-31	€6.31 Million ≈ $7.37 Million	+10.91%
2015-12-31	€5.69 Million ≈ $6.65 Million	+5.16%
2014-12-31	€5.41 Million ≈ $6.32 Million	+6.20%
2013-12-31	€5.09 Million ≈ $5.95 Million	+10.30%
2012-12-31	€4.62 Million ≈ $5.40 Million	+19.14%
2011-12-31	€3.87 Million ≈ $4.53 Million	+27.16%
2010-12-31	€3.05 Million ≈ $3.56 Million	+4.81%
2009-12-31	€2.91 Million ≈ $3.40 Million	+38.75%
2008-12-31	€2.10 Million ≈ $2.45 Million	--

About Integragen

PA:ALINT France Biotechnology

Market Cap

$1.38 Million

€1.18 Million EUR

Market Cap Rank

#30644 Global

#575 in France

Share Price

€0.18

Change (1 day)

+1.71%

52-Week Range

€0.13 - €0.36

All Time High

€7.02